Detection and treatment of depressive and anxiety disorders among cancer patients: Feasibility and preliminary findings from a liaison service in an oncology division

Depression and Anxiety

Volumn 23, Issue 7, 2006, Pages 441-448

  Pasquini, M ^a   Biondi, M ^a   Costantini, A ^b   Cairoli, F ^c   Ferrarese, G ^c   Picardi, A ^d   Sternberg, C ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; BREAST CANCER; CANCER PATIENT; COLON CANCER; DEPRESSION; FEASIBILITY STUDY; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; STRUCTURED CLINICAL INTERVIEW FOR DSM IV; STRUCTURED INTERVIEW;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CITALOPRAM; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIANSERIN; MIDDLE AGED; NEOPLASMS; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; PSYCHIATRY; REFERRAL AND CONSULTATION; SICK ROLE; TREATMENT OUTCOME;

EID: 33751039773     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20198     Document Type: Article

References (43)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author.
2. Ashbury FD, Madlensky L, Raich P. 2003. Antidepressant prescribing in community cancer care. Support Care Cancer 11:278-285.
3. Atesci FC, Baltalarli B, Oguzhanoglu NK, Karadag F, Ozdel O, Karagoz N. 2004. Psychiatric morbidity among cancer patients and awareness of illness. Support Care Cancer 12:161-167.
4. Beck AT, Ward C. 1962. Reliability of psychiatric diagnoses: A study of clinical judgements and ratings. Am J Psychiatry 19:351-356.
5. Bjelland I, Dahl AA, Haug TT, Neckelmann D. 2002. The validity of the Hospital Anxiety and Depression Scale: An updated literature review. J Psychosom Res 52:69-77.
6. Brennan J. 2001. Adjustment to cancer-coping or personal transition? Psychooncology 10:1-18.
7. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. 2005. Depression and anxiety in women with early breast cancer: Five year observational cohort study. BMJ 330:702-707.
8. Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G. 1999. Detecting psychological distress in cancer patients: Validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7:121-127.
9. Coyne JC, Thompson R, Palmer SC, Kagee A, Maunsell E. 2000. Should we screen for depression?: Caveats and potential pitfalls. Appl Prev Psychol 9:101-121.
10. Davis MP, Khawam E, Pozuelo L, Lagman R. 2002. Management of symptoms associated with advanced cancer: Olanzapine and mirtazapine: A World Health Organization project. Expert Rev Anticancer Ther 2:365-376.
11. Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetky S, Shamle AM, Henricks M, Carnickle Cl Jr. 1983. The prevalence of psychiatric disorders among cancer patients. JAMA 249:751-757.
12. First MB, Spitzer RL, Gibbon M, Williams JB. 2000. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-I CV) [Italian version by Mazzi F, Morosini P, de Girolamo G et al.]. Florence, Italy: Organizzazioni Speciali.
13. Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, Arquette MA, Brames MJ, Einhorn LH, Hoosier Oncology Group. 2003. Fluoxetine versus placebo in advanced cancer outpatients: A double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 21:1937-1943.
14. Grassi L, Albieri G, Rosti G, Marangolo M. 1987. Psychiatric morbidity after cancer diagnosis. Exp Clin Psychiatry 3:199-205.
15. Grassi L, Gritti P, Rigatelli M, Gala C. 2000. Psychosocial problems secondary to cancer: An Italian multicenter survey of consultation-liaison psychiatry in oncology. Eur J Cancer 36:579-585.
16. Grassi L, Rosti G. 1996. Psychiatric and psychosocial concomitants of abnormal illness behaviour in patients with cancer. Psychother Psychosom 65:246-252.
17. Hamilton, M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
18. Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. 1998. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 7:291-300.
19. Hopwood P, Howell A, Maguire P. 1991. Screening for psychiatric morbidity with advanced breast cancer: Validation of two self-report questionnaires. Br J Cancer 64:353-356.
20. Kathol RG, Mutgi A, Williams J, Clamon G, Noyes R Jr. 1990. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry 147:1021-1024.
21. Keller M, Sommerfeldt S, Fischer C, Knight L, Riesbeck M, Lowe B, Herfarth C, Lehnert T. 2004. Recognition of distress and psychiatric morbidity in cancer patients: A multi-method approach. Ann Oncol 15:1243-1249.
22. Kissane DW, Grabsch B, Love A, Clarke DM, Bloch S, Smith GC. 2004. Psychiatric disorder in women with early stage and advanced breast cancer: A comparative analysis. Aust NZ J Psychiatry 38:320-326.
23. Koriech OM. 1995. Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol (R Coll Radiol) 7:371-372.
24. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. 1998. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16:2377-2381.
25. Massie MJ, Holland JC. 1990. Depression and the cancer patient. J Clin Psychiatry 51:12-19.
26. Norusis MJ. 2002. SPSS 11.0 guide to data analysis. Upper Saddle River, NJ: Prentice-Hall .
27. Palmer SC, Coyne JC. 2003 Screening for depression in medical care: Pitfalls, alternatives, and revised priorities. J Psychosomatic Res 54:279-287.
28. Pancheri P, Picardi A, Gaetano P, Pasquini M, Puzella A, Di Fabio F, Biondi M. 1999. Validazione della scala per la valutazione rapida dimensionale "SVARAD." [Validation of the SVARAD] Riv Psichiatr 34:84-93.
29. Pasquini M, Picardi A, Biondi M, Gaetano P, Morosini P. 2004. Relevance of anger and irritability in outpatients with major depressive disorder. Psychopathology 37:155-160.
30. Picardi A, Morosni P, Gaetano P, Pasquini M, Biondi M. 2004. Higher levels of anger and aggressiveness in unipolar depression as compared with anxiety and somatoform disorders. J Clin Psychiatry 65:442-443.
31. Pirl WF, Roth AJ. 1999. Diagnosis and treatment of depression in cancer patients. Oncology 3:1293-1306.
32. Pirl WF, Siegel GI, Goode MJ, Smith MR. 2002. Depression in men receiving androgen deprivation therapy for prostate cancer: A pilot study. Psychooncology 11:518-523.
33. Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, Saltel P, Piollet I, Gauvain-Piquard A, Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth JP, Bouhassira M, Mesters P, Blin P. 1996. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94:205-210.
34. Razavi D, Delvaux N, Farvacques C, Robaye E. 1990. Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br J Psychiatry 156:79-83.
35. Richards S, Umbreit JN, Fanucchi MP, Giblin J, Khuri F. 2003. Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. South Med J 96:1031-1033.
36. Sellick SM, Crooks DL. 1999. Depression and cancer: An appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Psychooncology 8:315-333.
37. Sharpe M, Strong V, Allen K, Rush R, Postma K, Tulloh A, Maguire P, House A, Ramirez A, Cull A. 2004. Major depression in outpatients attending a regional cancer centre: Screening and unmet treatment needs. Br J Cancer 90:314-320.
38. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. 1989. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2:888-891.
39. Stefanek ME, Derogatis LR, Shaw A. 1997. Psychological distress among oncology outpatients: Prevalence and severity as measured by the Brief Symptom Inventory. Psychosomatics 28:530-539.
40. Tasmut T, Hartel B, Kalso E. 2002. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6:17-24.
41. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. 2002. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23:442-447.
42. Thompson DS. 2000. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 41:356-359.
43. Zabora J, Blanchard CG, Smith ED. et al. 1997. Prevalence of psychological distress among cancer patients across the disease continuum. J Psychosoc Oncol 15:73-87.